目錄:MedChemExpress LLC>>生化試劑>> Cemsidomide | MCE
CAS | 2504235-67-8 | 純度 | 98.94% |
---|---|---|---|
分子量 | 469.53 | 分子式 | C??H??N?O? |
供貨周期 | 現貨 | 規格 | 5 mg |
貨號 | HY-144841 | 應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 2504235-67-8
產品活性:Cemsidomide (CFT7455) is an orally active zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3) degrader. Cemsidomide is an anti-cancer agent that binds with high affinity to the cereblon E3 ligase (Kd of 0.9 nM) (WO2022032132A1; Compound 1).
研究領域:PROTAC
作用靶點:Ligands for E3 Ligase
In Vitro: Cemsidomide promotes the degradation of >75% of steady state IKZF1 in multiple myeloma cells within 1.5 hours at 0.3 nM. The high binding affinity and degradation catalysis of CFT7455 enables potent cell growth inhibition in both previously untreated NCIH929 multiple myeloma cell lines (IC50 of 0.071 nM) and NCIH929 cells made resistant to both lenalidomide and pomalidomide (IC50 of 2.3 nM).
Cemsidomide has potent antiproliferative activity against multiple myeloma cells and IMiD-resistant H929 cells.
In Vivo: In mouse xenograft tumor models, Cemsidomide demonstrates dose dependent efficacy from 3 μg/kg/day to 100 μg/kg/day. In several tumor xenografts tested daily dosing of Cemsidomide at dose of 30 μg/kg/day to 100 μg/kg/day led to durable tumor regression.
Cemsidomide (0.1 mg/kg/day; for 21 days) promotes tumor regression in the H929 tumor xenograft model (95% tumor growth inhibition by 7 days).
相關產品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Anti-Cancer Compound Library | Clinical Compound Library | Drug Repurposing Compound Library | Ubiquitination Compound Library | Orally Active Compound Library | Anti-Blood Cancer Compound Library | Transcription Factor-Targeted Library | E3 Ligase Ligand Library | Heterocyclic Compound Library | Lenalidomide hydrochloride | Thalidomide-NH-CH2-COOH | Pomalidomide-d3 | Thalidomide-5-propoxyethanamine | Pomalidomide-5-O-CH3 | BODIPY FL thalidomide | VH032-OH | TD-106 | SJPYT-195 | Lenalidomide-5-aminomethyl hydrochloride | BC-1215 | Thalidomide-5-propargyne-NH2 hydrochloride | Thalidomide 5-fluoride | VH032 thiol | Lenalidomide-5-Br | CRBN modulator-1 | E3 ligase Ligand 21 | Pomalidomide-C5-Dovitinib | Lenalidomide-6-F | E3 ligase Ligand 8 | LCL-PEG3-N3 hydrochloride | Thalidomide-5-PEG2-Cl | Golcadomide | Thalidomide-O-C8-COOH | CC-885 | ALV2 | Thalidomide-5-methyl | E3 ligase Ligand 13 | Pomalidomide-C11-NH2
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。